Skip to main content
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
58.45
-1.50 (-2.50%)
At close: Apr 28, 2026, 4:00 PM EDT
58.50
+0.05 (0.09%)
After-hours: Apr 28, 2026, 5:42 PM EDT

Boston Scientific Revenue by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
10.01B 9.50B 8.90B 8.35B 7.80B 7.32B 6.97B 6.71B
Cardiology Growth
28.40% 29.86% 27.65% 24.40% 20.24% 15.81% 13.75% 13.08%
Endoscopy
2.85B 2.78B 2.72B 2.69B 2.64B 2.59B 2.55B 2.48B
Endoscopy Growth
7.80% 7.18% 6.67% 8.22% 9.68% 10.86% 12.35% 11.75%
Peripheral Interventions
2.70B 2.60B 2.49B 2.41B 2.30B 2.23B 2.18B 2.11B
Peripheral Interventions Growth
17.54% 16.43% 14.41% 14.27% 11.99% 12.09% 12.55% 11.12%
Urology
2.62B 2.47B 2.32B 2.20B 2.10B 2.05B 2.01B 1.96B
Urology Growth
24.99% 20.65% 15.54% 12.02% 9.56% 9.87% 9.79% 10.77%
Neuromodulation
1.17B 1.14B 1.12B 1.11B 1.08B 1.04B 998.00M 976.00M
Neuromodulation Growth
8.47% 10.14% 12.22% 13.22% 12.45% 9.28% 5.83% 6.32%

Revenue by Geography
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
EMEA
3.35B 3.33B 3.27B 3.23B 3.15B 3.05B 2.95B 2.86B
EMEA Growth
6.36% 9.26% 11.03% 13.06% 13.90% 13.75% 12.70% 13.02%
United States
3.29B 3.22B 2.96B 2.89B 2.59B 2.47B 2.26B 2.21B
United States Growth
27.03% 30.74% 31.09% 30.73% 23.54% 16.87% 12.73% 11.43%
APAC
2.98B 2.86B 2.74B 2.69B 2.62B 2.54B 2.50B 2.40B
APAC Growth
13.76% 12.38% 9.56% 11.83% 12.75% 13.47% 16.50% 13.52%
LACA
654.00M 638.00M 631.00M 625.00M 618.00M 605.00M 583.00M 560.00M
LACA Growth
5.83% 5.45% 8.23% 11.61% 15.73% 19.33% 19.71% 19.66%

Operating Expense Breakdown
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
6.67B 6.49B 6.22B 5.98B 5.75B 5.43B 5.34B 5.19B
Selling, General, and Administrative Growth
15.91% 19.44% 16.45% 15.30% 15.62% 11.66% 14.20% 14.82%
Research and Development
1.94B 1.84B 1.69B 1.62B 1.52B 1.47B 1.44B 1.42B
Research and Development Growth
27.91% 25.07% 17.24% 14.20% 9.91% 7.55% 7.68% 6.95%
Amortization
894.00M 874.00M 862.00M 857.00M 840.00M 843.00M 840.00M 829.00M
Amortization Growth
6.43% 3.68% 2.62% 3.38% 2.44% 3.56% 3.96% 3.24%
Asset and Goodwill Impairment
- 157.00M - 387.00M - 277.00M - -
Asset and Goodwill Impairment Growth
- -43.32% - - - 52.20% - -
Restructuring Net Charges
89.00M 105.00M 23.00M 16.00M 31.00M 38.00M 53.00M 70.00M
Restructuring Net Charges Growth
187.10% 176.32% -56.60% -77.14% -45.61% -17.39% 29.27% 180.00%
Royalty Expense
50.00M 43.00M 38.00M 34.00M 36.00M 42.00M 45.00M 46.00M
Royalty Expense Growth
38.89% 2.38% -15.56% -26.09% -23.40% -10.64% -2.17% -2.13%
Contingent Consideration Net Expense
10.00M -24.00M -17.00M -5.00M 10.00M 45.00M 62.00M 57.00M
Contingent Consideration Net Expense Growth
- - - - - 150.00% 77.14% 62.86%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.